Comparative Pharmacology
Head-to-head clinical analysis: AZOLID versus PHENYLBUTAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZOLID versus PHENYLBUTAZONE.
AZOLID vs PHENYLBUTAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically interfering with peptidoglycan cross-linking.
Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby causing anti-inflammatory, analgesic, and antipyretic effects. It also inhibits leukocyte migration and lysosomal enzyme release.
2 g intravenously every 6-8 hours; maximum 8 g/day.
Oral: 100-200 mg three times daily with food; maximum 600 mg/day. For acute gout: initial 400 mg followed by 200 mg every 4-6 hours for 1-2 days, then reduce.
None Documented
None Documented
Clinical Note
moderatePhenylbutazone + Gatifloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePhenylbutazone + Rosoxacin
"Phenylbutazone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePhenylbutazone + Levofloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePhenylbutazone + Trovafloxacin
Terminal half-life 1.5-2 hours in normal renal function; prolonged to 4-8 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 50–65 hours, but exhibits dose-dependent kinetics; can extend to 72–100 hours with repeated dosing or in elderly.
Renal (80-90% unchanged), biliary/fecal (10-20%)
Primarily hepatic metabolism; renal excretion of metabolites (<1% unchanged). Biliary/fecal excretion accounts for ~20% of total elimination.
Category C
Category C
NSAID
NSAID
"Phenylbutazone may increase the neuroexcitatory activities of Trovafloxacin."